Carli (with her service dog Patience) and Erin (with her service dog Pine) talk about living with an ultra-rare disease in a new Ipsen-sponsored TikTok.

April 26, 2024 02:16 PM EDT

Marketing

Ipsen matches rare disease and TikTok influencers to create connections

Beth Snyder Bulik

Senior Editor

Ipsen’s new sponsored TikTok features the popular “Of course” trend and two social influencers, but with a rare disease twist. The short

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ipsen matches rare disease and TikTok influencers to create connections

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

Advocacy groups and experts call for decade-long ban on germline editing

Lack of detail in Trump's drug price plan raises more questions than answers

Ipsen match­es rare dis­ease and Tik­Tok in­flu­encers to cre­ate con­nec­tions

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Ipsen matches rare disease and TikTok influencers to create connections

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

Advocacy groups and experts call for decade-long ban on germline editing

Lack of detail in Trump's drug price plan raises more questions than answers